

Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4

Naggie S, et al. N Engl J Med 2015;378:705-13.

Ledipasvir-Sofosbuvir in GT1 or GT4 with HIV Coinfection

ION-4 Trial: Features

ION-4 Trial

- **Design:** Open-label, single group, phase 3 trial, using ledipasvir-sofosbuvir for 12 weeks in treatment-naïve or treatment-experienced patients with GT 1 or 4 and HIV coinfection
- **Setting:** multicenter in United States, Canada, New Zealand
- **Entry Criteria**
 - Chronic HCV Genotype 1 or 4
 - Treatment-naïve or treatment experienced
 - Noncirrhotic or compensated cirrhosis
 - Platelet count $> 50,000/\text{mm}^3$, hemoglobin ≥ 10 mg/dL, CrCl ≥ 60 mL/min
 - Stable ARV with HIV RNA < 50 copies/ml and CD4 count > 100 cells/ mm^3
 - ARV regimens: tenofovir-emtricitabine plus either efavirenz, rilpivirine, or raltegravir
- **End-Points:** Primary = SVR12; safety and tolerability

Ledipasvir-Sofosbuvir in GT1 or GT4 with HIV Coinfection

ION-4 Trial: Study Design

Week 0

12

24

GT 1 or 4
N = 335

Ledipasvir- Sofosbuvir

SVR12

Drug Dosing: Ledipasvir-sofosbuvir (90/400 mg): fixed dose combination; one pill once daily

Antiretrovirals allowed: tenofovir-emtricitabine plus either efavirenz, rilpivirine, or raltegravir

Ledipasvir-Sofosbuvir in GT1 or GT4 with HIV Coinfection

ION-4 Trial: Baseline Characteristics

Baseline Characteristic	Ledipasvir-Sofosbuvir (n = 335)
Mean age, years	52
Male, n (%)	276 (82)
African American, n (%)	115 (34)
Hispanic or Latino, n (%)	56 (17)
Mean BMI, kg/m ²	26
IL28B CC, n (%)	81 (24)
GT 1 (%)	327 (98)
HCV treatment experienced, n (%)	185 (55)
Cirrhosis, n (%)	67 (20)
Mean HCV RNA, log ₁₀ IU/mL	6.7 ± 0.6
Median CD4 Count, cells/mm ³ (range)	628 (100-2069)

Ledipasvir-Sofosbuvir in GT1 or GT4 with HIV Coinfection


ION-4 Trial: Antiretroviral Regimens

ION-4: HIV Antiretroviral Regimen	
Antiretroviral Agent	Antiretroviral Received (n = 335)
Tenofovir-emtricitabine-efavirenz	160 (48)
Tenofovir-emtricitabine-rilpivirine	29 (9)
Tenofovir-emtricitabine + Raltegravir	146 (44)

Ledipasvir-Sofosbuvir in GT1 or GT4 with HIV Coinfection

ION-4 Trial: Results


ION-4: SVR12 Results by Genotype



Ledipasvir-Sofosbuvir in GT1 or GT4 with HIV Coinfection

ION-4 Trial: Results

ION-4: SVR12 Results by Prior Treatment Status and Liver Status



Ledipasvir-Sofosbuvir in GT1 or GT4 with HIV Coinfection

ION-4 Trial: Adverse Effects

Event	Ledipasvir-Sofosbuvir (n = 335)
Discontinuation due to adverse event	0
Grade 3-4 Adverse Event	14 (4%)
Serious Adverse Event	8 (2%)
Headache	83 (25%)
Fatigue	71 (21%)
Diarrhea	36 (11%)
Nausea	33 (10%)
Arthralgia	22 (7%)
Upper respiratory tract infection	18 (5%)
Vomiting	14 (4%)
Muscle spasms	11 (3%)

Ledipasvir-Sofosbuvir in GT1 or GT4 with HIV Coinfection ION-4 Trial: Conclusions

Conclusions: “Ledipasvir and sofosbuvir for 12 weeks provided high rates of sustained virologic response in patients coinfecting with HIV-1 and HCV genotype 1 or 4.”

This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online

www.hepatitisc.uw.edu

Hepatitis Web Study

<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.